| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Atara Biotherapeutics, Inc.$9.76
-0.19 (-1.86%)
D 33Pipeline Score Overvalued Biotech · Commercial
Market Cap
89.20 M
EPS
-0.88
P/E Ratio
-11.24 $
Value Trade
995.87 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
516.00 K
R&D Expenses
164.00 K
Operating CF
-3.07 M
Total Assets
20.00 M
Total Liabilities
57.31 M
Equity
-37.31 M
D/E Ratio
12,345
0.93 %
Week
96.39 %
1 Month
130.05 %
3 Month
-26.54 %
6 Month
-97.29 %
5 Year
-96.04 %
All Time
Cash Data
Cash Position
16.47 M
Monthly Burn
1.02 M
Runway
14.4 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
66.88 K
52 Week Range
3.92 - 19.15
% held by Insiders
33.4 %
% held by Institutions
48.4 %
Enterprise Value
132.40 M
Total Shares
7.20 M
Short %
8.21 %
Float Shares
2.59 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Atara Biotherapeutics, Inc.
564Total events
2Upcoming
138Tier-1 (high impact)
2014 – 2028Coverage
Upcoming catalysts 2
Event history 562
Q3 2026
◆CRL ResubmissiontabelecleucelFDA Decision
Intended resubmission of tab-cel BLA with updated dataset from ALLELE study
R/R EBV+ PTLD following solid organ transplant or hematopoietic cell transplantsource ↗
Q3 2026
◆Timing GuidancetabelecleucelPresentation
Regulatory update expected in Q3 2026
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
May 22, 2026
May 22, 2026
◆Timing GuidancePresentation
Deadline to request lead plaintiff appointment in class action lawsuit
May 12, 2026
▲FDA Feedback ReceivedtabelecleucelFDA Meeting
Productive FDA meeting; path forward for BLA resubmission discussed
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
May 7, 2026
◆Type A MeetingtabelecleucelFDA Meeting
Type A meeting with FDA to discuss CRL for tab-cel BLA
R/R EBV+ PTLD following solid organ transplant or hematopoietic cell transplantsource ↗
Apr 20, 2026
▼Short Report ActivistCorporate
Securities class action lawsuit filed against Atara Biotherapeutics
Q2 2026
◆Type A MeetingtabelecleucelFDA Meeting
Type A meeting scheduled with FDA to discuss CRL issues
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
Q2 2026
◆Timing GuidancetabelecleucelPresentation
Regulatory update expected in Q2 2026
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
Mar 16, 2026
◆Type A MeetingtabelecleucelFDA Meeting
Type A meeting scheduled between Pierre Fabre and FDA to discuss CRL
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
Drug Pipeline Intelligence
D33
Pipeline Score $29M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.3x
rNPV / MCap Top 43%
Micro Cap (rank 520 of 911)
Percentile RankAtara Biotherapeutics, Inc. faces pipeline headwinds (33/100), with $633M risk-adjusted pipeline value, led by WT1-sensitized T cells in Leukemia (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WT1-sensitized T cells Monoclonal antibody | Leukemia | Phase 1 | NCT00620633 | 17% | $514M | COMPLETED | 22 | - | - | Feb 26, 2021 | - | Mar 2, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ATA188 | non-active progressive multiple sclerosis | Phase 2 | 2023-11-08 | disability improvement treatment arm: 6 percent; disability improvement placebo: 33 percent; placebo rate: 16 percent; expected placebo rate: 4-6 percent Read More | Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 for Non-Active Progressive Multiple Sclerosis Primary Endpoint of Confirmed Disability Improvement at 12 Months Not Achie Read More | |
ATA188 | non-active progressive multiple sclerosis | Phase 2 | 2023-11-08 | disability improvement treatment arm: 6 percent; disability improvement placebo: 33 percent; placebo rate: 16 percent; expected placebo rate: 4-6 percent Read More | Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 for Non-Active Progressive Multiple Sclerosis Primary Endpoint of Confirmed Disability Improvement at 12 Months Not Achie Read More | |
ATA188 | non-active progressive multiple sclerosis | Phase 2 | 2023-11-08 | disability improvement treatment arm: 6 percent; disability improvement placebo: 33 percent; placebo rate: 16 percent; expected placebo rate: 4-6 percent Read More | Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 for Non-Active Progressive Multiple Sclerosis Primary Endpoint of Confirmed Disability Improvement at 12 Months Not Achie Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ATRA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ATRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ATRAAtara Biotherapeutics Announces Changes to Its Board of Directors
Atara Biotherapeutics has announced changes to its Board of Directors. The details regarding the specific changes or the implications of these adjustments were not disclosed in the article. This announcement reflects the company's ongoing efforts to align its leadership with its strategic goals.
Read more →ATRAATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
Rosen Law Firm is reminding investors in Atara Biotherapeutics, Inc. (ATRA) about an upcoming deadline related to a securities class action lawsuit. Investors who purchased securities between May 20, 2024, and January 9, 2026, may be eligible for compensation without out-of-pocket fees. The lawsuit alleges that Atara misrepresented regulatory prospects for their tabelecleucel drug due to manufacturing issues and deficiencies in trial studies. Investors are encouraged to seek counsel before the May 22, 2026, deadline to act as lead plaintiffs in the case.
Read more →ATRA▼ -8.5%on this newsshared move
ATARA DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
Rosen Law Firm is urging investors of Atara Biotherapeutics, Inc. who purchased securities between May 20, 2024, and January 9, 2026, to join a class action lawsuit due to alleged misleading statements by the company. The lawsuit highlights deficiencies in manufacturing and clinical trials that could hinder the FDA approval of their drug tabelecleucel. Investors are reminded to secure counsel by May 22, 2026, to potentially serve as lead plaintiffs. The firm aims to represent investors in pursuing claims for damages resulting from these alleged misrepresentations.
Read more →ATRA▲ +11.7%on this newsshared move
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
Atara Biotherapeutics has announced its financial results and operational progress for the first quarter of 2026. The report highlights the company's ongoing efforts and developments in its therapeutic pipeline. However, specific details regarding financial performance and operational milestones were not disclosed in the article.
Read more →ATRA▲ +5.3%on this news· ran to +18% by day 1shared move
Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights – ATRA
Atara Biotherapeutics, Inc. is currently facing a class action securities lawsuit initiated by Levi & Korsinsky, LLP on behalf of investors affected by alleged securities fraud occurring between May 2024 and January 2026. The lawsuit alleges that the company made false statements regarding manufacturing issues and the likelihood of FDA approval for its product, tabelecleucel. This has raised concerns about the company's regulatory standing and the potential impact on its business and financial condition. Affected investors have until May 22, 2026, to act as lead plaintiffs in the case.
Read more →ATRA▲ +92.8%on this newsshared move
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Eps
Atara Biotherapeutics has provided an update on the regulatory progress of tabelecleucel following a Type A meeting with the FDA. The meeting discussed a potential pathway for resubmitting the Biologics License Application (BLA) for tabelecleucel, where the FDA indicated that a single arm study with appropriate historical controls could be adequate. Pierre Fabre Pharmaceuticals plans to submit additional patient data from the Phase 3 ALLELE study as part of the resubmission. Atara expressed gratitude for the collaborative engagement with the FDA and anticipates further updates in the third quarter.
Read more →ATRA▼ -5.3%on this news
Atara Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights – ATRA
Atara Biotherapeutics is facing a class action securities fraud lawsuit initiated by investors claiming they incurred losses due to misleading statements made by the company. The lawsuit alleges that Atara concealed critical manufacturing issues and deficiencies in the ALLELE study, raising concerns about the regulatory approval of tabelecleucel. The affected timeframe for the alleged fraud is between May 20, 2024, and January 9, 2026. Investors have until May 22, 2026, to act as lead plaintiffs in the case.
Read more →ATRA▼ -9.7%on this news· ran to -21% by day 3
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
Atara Biotherapeutics has announced its financial results for Q4 and full year 2025, showing a reduced net loss compared to 2024. The company is focusing on cost-reduction strategies while supporting its partner, Pierre Fabre Pharmaceuticals, in addressing FDA concerns regarding tabelecleucel for post-transplant lymphoproliferative disease. A Type A meeting with the FDA is scheduled to discuss these issues.
Read more →ATRA▼ -9.7%on this news· ran to -21% by day 3
Atara Biotherapeutics, Inc. Consolidated Statements of Operations and Comprehensive Income (Loss) (In thousands, except per share amounts) Years Ended
Atara Biotherapeutics released its financial results for the fourth quarter and full year 2025, highlighting operational efficiencies and a cash runway extension to the end of 2026. The company remains supportive of Pierre Fabre Pharmaceuticals as they prepare for a Type A meeting with the FDA regarding tabelecleucel's regulatory status. Despite a reduction in operating expenses and a focus on cost-cutting measures, Atara reported a net loss for the year. Additionally, there was a slight decrease in commercialization revenues compared to the previous year, raising some concerns about future financial performance.
Read more →ATRA▲ +10.4%on this news
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
Atara Biotherapeutics announced that its partner, Pierre Fabre Pharmaceuticals, has requested a Type A meeting with the FDA regarding tabelecleucel. This follows the submission of a briefing book addressing concerns from a previous Complete Response Letter. The company aims to discuss the path forward for tabelecleucel, which addresses an urgent need in the PTLD community.
Read more →ATRAAtara Biotherapeutics Provides a Business Update
Atara Biotherapeutics announced an amendment to its agreement with HealthCare Royalty, extending a $9 million cash payment due date to January 1, 2028. This extension allows Atara to focus on addressing FDA concerns related to tabelecleucel, a therapy for EBV+ PTLD. The company remains optimistic about its potential and the need for treatment options in the U.S.
Read more →ATRAAtara Biotherapeutics Provides a Business Update Atara renegotiates one-time milestone payment with HCRx THOUSAND OAKS, California -(BUSINESS WIRE)- Atara Biotherapeutics, Inc . (Nasdaq: ATRA), a leader in T-cell immunot
Atara Biotherapeutics has announced a renegotiation of their $9.0 million milestone payment with HealthCare Royalty. The due date has been extended from June 30, 2026, to January 1, 2028, which will allow Atara to focus on addressing regulatory concerns related to its therapy tabelecleucel. The company's CEO expressed optimism about this therapy's potential for European patients with an ultra-rare form of lymphoma. Additionally, Atara issued a warrant for shares as part of the agreement amendments.
Read more →ATRAAtara Biotherapeutics Provides Regulatory and Business Update on EBVALLO (tabelecleucel) U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) THOUSAND OAKS, Calif. -(BUSINESS WIRE)- Atara Biother
Atara Biotherapeutics announced that the FDA has issued a Complete Response Letter for its biologics license application (BLA) for EBVALLO (tabelecleucel). The letter indicated that the FDA can no longer support the adequacy of the ALLELE trial, despite prior confirmations. While Atara has resolved previously identified GMP compliance issues, they now face new challenges regarding trial design. Atara plans to work with Pierre Fabre and the FDA to navigate a path towards accelerated approval for this treatment, which serves patients with limited options.
Read more →ATRAAtara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of
Atara Biotherapeutics reported its third quarter financial results and detailed its progress regarding the Biologics License Application (BLA) for tab-cel, aimed at treating EBV+ PTLD. The BLA has been accepted by the FDA with a target action date set for January 10, 2026. Additionally, Atara has transitioned much of its tab-cel operations to Pierre Fabre, allowing for potential milestone payments. However, the company announced a workforce reduction of approximately 29%, which may affect its strategic execution moving forward.
Read more →ATRA▼ -5.8%on this news
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of
Atara Biotherapeutics reported its second-quarter financial results highlighting operational progress and announced the resubmission of its Biologics License Application (BLA) for tab-cel for EBV+ PTLD. The BLA has been given Priority Review with a target action date of January 10, 2026. The company has transferred its tab-cel activities to Pierre Fabre Laboratories and expects a $40 million milestone payment upon the BLA's approval. Despite a decrease in total revenues year-over-year, Atara anticipates an overall decrease in operating expenses for 2025, enhancing its financial position.
Read more →ATRAAtara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel ) Atara Biotherapeutics Resubmits Tabelecleucel (Tab-cel ) Biologics License Application for Treatment of Epstein-Barr Virus Positi
Atara Biotherapeutics has announced the resubmission of its Biologics License Application (BLA) for tabelecleucel (tab-cel) to the U.S. FDA for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease. The resubmission addresses previous manufacturing concerns raised by the FDA and is backed by strong clinical data. Upon approval, Atara is set to receive a $40 million milestone payment from Pierre Fabre Laboratories, highlighting potential financial benefits. However, uncertainties surrounding cash flow and timeline for FDA review present risks for the company.
Read more →ATRA▲ +15.1%on this news
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufa
Atara Biotherapeutics reported its first quarter 2025 financial results, highlighting significant operational changes. The company has transferred all manufacturing responsibilities to Pierre Fabre Laboratories and expects to reduce operating expenses by 65% by 2025. Additionally, Atara secured $16 million in financing to extend its cash runway through early 2026 while assessing strategic options for future operations. Despite these positive developments, the company is facing regulatory uncertainties, including a pending Type A meeting with the FDA regarding its BLA submission for tab-cel.
Read more →ATRAAtara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO BLA resubmissi
Atara Biotherapeutics reported its fourth quarter and full year 2024 financial results, revealing a focus on the EBVALLO program amidst significant operational changes. The company is currently engaged with the FDA to resolve issues preventing the submission of a Biologics License Application (BLA) for EBVALLO after receiving a Complete Response Letter. In efforts to streamline operations, Atara has paused CAR-T program developments and cut its workforce by about 50%. Financial results indicate a reduced net loss; however, ongoing challenges with funding and clinical holds remain.
Read more →ATRA▼ -7.9%on this news· ran to +25% by day 3
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO TM (tabelecleucel) and ATA3219 U.S. FDA issues clinical hold on EBVALLO TM (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Resp
Atara Biotherapeutics has announced that the U.S. FDA has placed a clinical hold on its EBVALLO and ATA3219 clinical programs. This hold is due to GMP compliance issues at a third-party manufacturing facility, which have been linked to a recent Complete Response Letter. While treatment for existing patients can continue, new patient enrollment has been paused. Atara is collaborating with the FDA to address the concerns and intends to submit the necessary data to resolve the hold.
Read more →ATRA▼ -40.5%on this newsshared move
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO TM (tabelecleucel) Atara received FDA Complete Response Letter (CRL) solely related to inspection findings at third-party manufacturer CRL did not
Atara Biotherapeutics has received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application for EBVALLO (tabelecleucel), which was primarily related to inspection findings at a third-party manufacturing facility. The CRL did not raise any concerns regarding the drug's clinical efficacy or safety data, and no new clinical trials are required for approval. In response, Atara is exploring strategic options and has entered into a term sheet for $15 million in funding, while also emphasizing its commitment to preserving the financial value of EBVALLO for shareholders. The company will work to address the feedback and prepare for a possible resubmission to the FDA within six months.
Read more →ATRAAtara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress Tab-cel U.S. BLA On-Track With PDUFA Target Action Date of
Atara Biotherapeutics reported its third quarter 2024 financial results, highlighting progress in its pipeline with tab-cel's BLA on track for FDA approval by January 2025. The company has initiated a Phase 1 clinical trial for ATA3219 targeting Non-Hodgkin's lymphoma, with initial data expected in Q1 2025. Atara's cash position has improved significantly, enabling operations through 2027, though it continues to face legal and financial challenges, including a notable net loss this quarter.
Read more →ATRA▼ -10.4%on this news· ran to +25% by day 3
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of
Atara Biotherapeutics has entered into a Securities Purchase Agreement with several purchasers for the sale of its securities, set to take place on September 5, 2024. The Agreement outlines the terms under which the company will issue and sell these securities, defined in detail throughout the contract. The offer is subject to an effective registration statement under the Securities Act, with specific conditions and definitions provided in the Agreement. As of now, no specific risks or benefits are highlighted within the article itself.
Read more →ATRAAtara Biotherapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except per share amounts) Three Months Ended June 30, Six Months Ended
Atara Biotherapeutics announced its second-quarter financial results along with key operational highlights and a leadership update. The FDA accepted the Biologics License Application for tab-cel with a Priority Review, targeting an action date of January 15, 2025. The company provided timelines for the initiation of the ATA3219 studies in lupus nephritis and non-Hodgkin's lymphoma, with initial data expected in 2025. Leadership changes include Pascal Touchon stepping down as CEO and Cokey Nguyen being appointed to the role.
Read more →ATRAAtara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel ) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferati
Atara Biotherapeutics has announced that the FDA has accepted its Biologics License Application (BLA) for tabelecleucel (tab-cel), a treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). The BLA has been granted priority review with a target action date of January 15, 2025. If approved, tab-cel would become the first approved therapy for this condition in the U.S., addressing a significant unmet medical need. Additionally, the acceptance of the BLA triggers a $20 million milestone payment from Pierre Fabre Laboratories, with the potential for an additional $60 million if the FDA approves tab-cel.
Read more →ATRA▼ -16.9%on this news· ran to -36% by day 3
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
Atara Biotherapeutics has announced a 1-for-25 reverse stock split of its common stock, effective on June 20, 2024. The decision aims to help the company regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. Shareholders approved this action during the Annual Meeting on June 10, 2024. As a result, the number of outstanding shares will decrease significantly, directly impacting the company's stock and potential future equity awards.
Read more →ATRAAtara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress Tab-cel U.S. BLA on Track for Submission in Q2 2024 Initiation of ATA3219 Lupus Nephritis Study Expected in Q4 2024, with Init
Atara Biotherapeutics reported its first quarter 2024 financial results, highlighting significant progress in its clinical pipeline. The company is on track to submit a Biologics License Application (BLA) for tab-cel in Q2 2024 and plans to initiate a study for ATA3219 targeting lupus nephritis in Q4 2024. Financially, Atara saw a substantial revenue increase but reported increased cash expenditures, raising some concerns about operational sustainability. The partnerships and strategic advancements are expected to enhance the company's trajectory in the coming months.
Read more →ATRAAtara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Tab-cel U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting Allogeneic CAR T Pipelin
Atara Biotherapeutics announced its financial results for Q4 and the full year of 2023, highlighting significant operational updates. The company is gearing up for the submission of its Biologics License Application for tab-cel in Q2 2024 after a positive engagement with the FDA. Additionally, Atara is expanding its pipeline into autoimmune diseases, specifically with plans for a lupus nephritis study expected to begin in H2 2024. Despite its promising developments, Atara reported substantial financial losses and has undertaken significant workforce reductions to manage costs.
Read more →ATRA▲ +25.3%on this news· ran to +36% by day 3
Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Atara Biotherapeutics is presenting forward-looking statements regarding its product candidates, business strategies, and future financial prospects at the upcoming J.P. Morgan Healthcare Conference. The company has recently expanded its partnership with Pierre Fabre Laboratories, which includes significant potential royalties and reimbursement for development costs of its tab-cel product. Additionally, Atara is preparing for a biologics licensing application (BLA) submission for tab-cel in Q2 2024, backed by favorable clinical data. However, the company faces uncertainties related to the global economic environment and the pharmaceutical development process.
Read more →ATRAAtara Biotherapeutics Announces Closing of Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories THOUSAND OAKS, Calif.—
Atara Biotherapeutics has finalized an expanded global partnership with Pierre Fabre Laboratories regarding its T-cell therapy, tab-cel. This agreement gives Pierre Fabre the rights to develop and commercialize tab-cel in the U.S. and other markets. As a result, Atara will receive USD 27 million upfront and has the potential for up to USD 640 million in future payments and royalties. The company plans to submit a Biologics License Application (BLA) for tab-cel by the second quarter of 2024, marking significant progress in its commercialization efforts.
Read more →ATRA▼ -9%on this news· ran to -82% by day 1
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 for Non-Active Progressive Multiple Sclerosis Primary Endpoint of Confirmed Disability Improvement at 12 Months Not Achie
Atara Biotherapeutics reported that its Phase 2 EMBOLD clinical trial of ATA188 for non-active progressive multiple sclerosis did not achieve its primary endpoint of confirmed disability improvement after 12 months. The study also failed to provide supportive evidence through fluid and imaging biomarkers. Preliminary safety data were favorable, with no new safety signals. Following these results, Atara plans to shift its focus and resources towards its allogeneic CAR-T pipeline and reduce expenses related to the ATA188 program.
Read more →ATRAAtara Biotherapeutics Announces Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel , inclu
Atara Biotherapeutics has expanded its global partnership with Pierre Fabre Laboratories to commercialize tab-cel, a therapy for certain cancers. The agreement includes up to $640 million in payments and funding for global development costs, extending Atara's financial runway into Q3 2025. However, the company is also restructuring its operations, resulting in a 30% workforce reduction. Atara plans to focus on its pipeline, including upcoming clinical studies for its therapies, highlighting its commitment to innovative cancer treatments.
Read more →ATRAAtara Biotherapeutics Announces Plans to Submit Tab-cel BLA in Q2 2024 Following FDA Agreement on Comparability
Atara Biotherapeutics is advancing its regulatory pathway for tabelecleucel (tab-cel) with plans to submit a Biologics License Application (BLA) in Q2 2024, following an alignment with the FDA on analytical comparability in manufacturing processes. This development allows Atara to combine clinical trial data from different manufacturing versions into the BLA submission. Tabelecleucel is an EBV-specific immunotherapy for patients suffering from EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD), a condition with limited treatment options and poor survival rates. The positive discussions with the FDA mark a significant step in bringing this potentially life-saving treatment to market.
Read more →ATRAAtara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress Discussions With FDA Progressing on Potential BLA Submission for Tab-cel With Meeting Scheduled To Resolve Remaining Topic of
Atara Biotherapeutics has announced its financial results for the second quarter of 2023, reporting a net loss of $71.1 million. The company received IND clearance for ATA3219, its first allogeneic CAR T candidate, while discussions with the FDA regarding a potential BLA submission for tab-cel are ongoing. Atara also plans to release data from the ATA188 Phase 2 EMBOLD study in November 2023.
Read more →ATRAAtara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress First Patients Treated in Europe with EBVALLO TM Following Transfer of EC Marketing Authorization to Pierre Fabre; Discussions
Atara Biotherapeutics reported its first quarter 2023 financial results, showing continued operational progress, including the treatment of its first patients in Europe with EBVALLO. The company is making strides in its various clinical programs, planning to present data from the ATA188 Phase 2 EMBOLD study by October 2023 and anticipating the filing of an IND for ATA3219 by the end of Q2 2023. However, Atara also disclosed significant net losses and a decrease in cash resources, alongside notable executive departures, posing potential challenges for its ongoing development efforts.
Read more →ATRA▼ -7.7%on this news· ran to -19% by day 3
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress Ebvallo EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023 Discussions with FDA Progressing on Pot
Atara Biotherapeutics has announced its fourth quarter and full year 2022 financial results, showcasing significant milestones, including the upcoming launch of Ebvallo in Europe and productive discussions with the FDA regarding tab-cel’s BLA. The company is also on track for the primary data readout of its Phase 2 EMBOLD study for ATA188 in October 2023 and expects its cash runway to extend into Q2 2024. However, it reported considerable net losses during this period, raising concerns about its financial health.
Read more →ATRAAtara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress Ebvallo TM Positioned to be the First Allogeneic T-Cell Therapy Ever Approved Following CHMP Positive Opinion New ATA188 Bioma
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress EbvalloTM Positioned to be the First Allogeneic T-Cell Therapy Ever Approved Following CHMP Positive Opinion New ATA188 Biomarker Imaging Data Show Less Brain Atrophy and Possible Remy
Read more →ATRA▲ +5.5%on this news· ran to +36% by day 1
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update Atara to Focus on R&D Activities Prioritizing Upcoming Milestones for Key Pipeline Assets ATA188 Phase 2 EMBOLD Study In
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update Atara to Focus on R&D Activities Prioritizing Upcoming Milestones for Key Pipeline Assets ATA188 Phase 2 EMBOLD Study Interim Analysis Completed with Target Enrollment Achieved;
Read more →ATRA▼ -6.7%on this news· ran to -22% by day 3
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress FDA Fast-Track Designated ATA188 Interim Analysis On-Track for June 2022 Tab-cel Anticipated European Commission Approval On-T
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress FDA Fast-Track Designated ATA188 Interim Analysis On-Track for June 2022 Tab-cel Anticipated European Commission Approval On-Track for Q4 2022; Dialogue with FDA Ongoing Cash Expected
Read more →ATRAAtara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress Tab-cel U.S. BLA Submission Not Currently Expected for Q2 2022 as Further FDA Engagement and Alignment Required
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress Tab-cel U.S. BLA Submission Not Currently Expected for Q2 2022 as Further FDA Engagement and Alignment Required; Anticipated EU Approval On-Track for Q4 2022 Under Accele
Read more →ATRAAtara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm Fujifilm to Acquire Atara s Cell Therapy Manufacturing Facility for Total Upfront Financial Consideration of USD 100 Million Parties to Enter
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm Fujifilm to Acquire Atara s Cell Therapy Manufacturing Facility for Total Upfront Financial Consideration of USD 100 Million Parties to Enter Long-Term Supply Agreement for Clinical and Commercial Pr
Read more →ATRAOla EBV+ PTLD Advocate ATARA BIO Investor Presentation JP Morgan Healthcare Conference
Ola EBV+ PTLD Advocate ATARA BIO Investor Presentation JP Morgan Healthcare Conference January 10, 2022 Nasdaq: ATRA Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provision
Read more →ATRAAtara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress Positive Pivotal Phase 3 ALLELE Data Reinforcing the Transformative Potential of Tab-cel to be Highlighted as Oral Presentatio
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress Positive Pivotal Phase 3 ALLELE Data Reinforcing the Transformative Potential of Tab-cel to be Highlighted as Oral Presentation at Upcoming American Society of Hematology Meeting Sign
Read more →ATRAAtara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress Progress with FDA on evaluating tab-cel product comparability and new robust Phase 3 ALLELE study data Recent positive milest
Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress Progress with FDA on evaluating tab-cel product comparability and new robust Phase 3 ALLELE study data Recent positive milestones with EMA provide clear path for EU Marketing Authoriz
Read more →ATRAAtara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast Today at 4:30 p.m. EDT SOUTH SAN FRANCISCO, Calif., May 4 -- Atara Biotherapeutics, Inc. (Nasdaq:
Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast Today at 4:30 p.m. EDT SOUTH SAN FRANCISCO, Calif., May 4 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its n
Read more →ATRAAtara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress On track to complete the rolling tab-cel BLA submission in Q3 2021 for patients with EBV + PTLD through active
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress On track to complete the rolling tab-cel BLA submission in Q3 2021 for patients with EBV+ PTLD through active and productive discussions with FDA On track with ATA188 Ph
Read more →ATRAAtara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress Interim Analysis of the pivotal 302 study (ALLELE) showed tab-cel in EBV + PTLD achieved a 50 percent objective response rate
Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress Interim Analysis of the pivotal 302 study (ALLELE) showed tab-cel in EBV+ PTLD achieved a 50 percent objective response rate and safety consistent with historical data Discussions with
Read more →ATRAAtara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress - Company to host conference call today at 4:30 p.m. EDT
Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress - Company to host conference call today at 4:30 p.m. EDT - SOUTH SAN FRANCISCO, Calif., August 5, 2020 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy,
Read more →ATRAAtara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress - Company to host conference call today at 4:30 p.m. EST
Atara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress - Company to host conference call today at 4:30 p.m. EST - SOUTH SAN FRANCISCO, Calif., May 6, 2020 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, lev
Read more →ATRAAtara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
Atara Biotherapeutics reported its financial results for Q4 and the full year of 2019, highlighting strategic advancements in T-cell immunotherapy programs. The company aims to achieve key milestones in 2020, focusing on its EBV T-cell platform and CAR T technologies. CEO Pascal Touchon emphasized the commitment to transforming patient lives through innovative science.
Read more →ATRAAtara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics has reported the grant of inducement awards to Kristin Yarema, its Chief Commercial Officer. The awards include a stock option for 110,000 shares and restricted stock units for 55,000 shares, effective February 18 and March 1, 2020, respectively. These grants are part of the company's compliance with Nasdaq Listing Rule 5635(c)(4). Atara is focused on developing novel treatments for cancer and other diseases.
Read more →ATRAAtara Biotherapeutics to Participate at Two Upcoming Investor Conferences
Atara Biotherapeutics will participate in two investor conferences in March 2020. CEO Pascal Touchon will present at the Cowen 40th Annual Health Care Conference and the Barclays Global Healthcare Conference. Live webcasts of the presentations will be available on the company's website, enhancing investor engagement and visibility.
Read more →ATRAAtara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
Atara Biotherapeutics will announce its fourth quarter and full year 2019 financial results on February 27, 2020. A conference call will follow the announcement to discuss the results and provide a corporate update. The company is known for its allogeneic T-cell immunotherapy developments targeting various diseases.
Read more →ATRAAtara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer
Atara Biotherapeutics has appointed Kristin Yarema as Chief Commercial Officer, effective February 18, 2020. Yarema, who has over 20 years of experience in the biopharmaceutical sector, previously held a senior role at Amgen. Her expertise is expected to strengthen Atara's commercial strategy and support the launch of their products, particularly tab-cel®.
Read more →ATRAAtara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics will present its key milestones and progress in developing off-the-shelf, allogeneic T-cell immunotherapies at the 38th Annual J.P. Morgan Healthcare Conference. CEO Pascal Touchon will discuss the company's mission and pipeline, highlighting advancements in their EBV T-cell platform and CAR T technologies. The presentation is scheduled for January 16, 2020.
Read more →ATRAAtara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting
Atara Biotherapeutics presented updated long-term results from a multicenter Expanded Access Protocol study for tab-cel® in patients with EBV+ PTLD at the ASH Annual Meeting. The study showed a high overall response rate and favorable two-year survival rates, particularly in patients who had undergone solid organ transplants. Tab-cel® was well-tolerated, with no treatment-related discontinuations reported.
Read more →ATRAAtara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference
Atara Biotherapeutics will participate in the Evercore ISI Second Annual HealthCONx Conference on December 3, 2019. CEO Pascal Touchon is scheduled for a fireside chat at the event in Boston, MA. A live audio webcast will be available, with an archived replay for 14 days post-event. Atara focuses on off-the-shelf T-cell immunotherapy for various diseases.
Read more →ATRAAtara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress SOUTH SAN FRANCISCO, Calif., November 7, 2019 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy compa
Read more →ATRAAtara Biotherapeutics to Present Tab-cel Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting
26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® EAP study including a subgroup of 22 patients who would have likely met eligibility criteria for Atara’s ongoing tab‑cel® Phase 3 studies An overall response rate (ORR) of 55 and 82 percent was obse
Read more →ATRAAtara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it
Read more →ATRAAtara Biotherapeutics Announces Executive Departures
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the dep
Read more →ATRAAtara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
Enrollment in the fourth and final planned Phase 1 dose escalation cohort completed ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, believed to play a role in the pathogenesis of multiple sclerosis Conference call and webcast today at 3:30 p.m. CEST / 9:30 a.m. EDT S
Read more →ATRAAtara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, which we believe play a fundamental role in the pathogenesis of multiple sclerosis Conference call and webcast to discuss results Friday, September 13, 2019, at 3:30 p.m. CEST/ 9:30 a.m. EDT SOUTH SAN FRANCISCO, Calif.,
Read more →ATRAAtara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Pa
Read more →ATRAAtara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress
Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress SOUTH SAN FRANCISCO, Calif., August 8, 2019 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treat
Read more →ATRAAtara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it
Read more →ATRAAtara Biotherapeutics Announces Pricing of $150.0 Million Public Offering
SOUTH SAN FRANCISCO, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the pric
Read more →ATRAAtara Biotherapeutics Announces Proposed Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it
Read more →ATRAAtara Biotherapeutics Announces Plan to Initiate Tab-cel FDA Biologics License Application Submission Next Year
SOUTH SAN FRANCISCO, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced an upda
Read more →ATRAAtara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)
SOUTH SAN FRANCISCO, Calif., June 29, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced initial
Read more →ATRAAtara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 25, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the gran
Read more →ATRAAtara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
Memorial Sloan Kettering Cancer Center collaborators presented results demonstrating that a regionally delivered mesothelin-targeted, autologous CAR T was well tolerated and showed encouraging anti-tumor activity in combination with pembrolizumab, a PD-1 checkpoint inhibitor In
Read more →ATRAAtara Biotherapeutics Presents Tab-cel Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 01, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today presented results
Read more →ATRAAtara Biotherapeutics Appoints Pascal Touchon President, Chief Executive Officer and Member of the Board of Directors
SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the appo
Read more →ATRAAtara Biotherapeutics Announces Presentation of Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)
SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced a presen
Read more →ATRAAtara Biotherapeutics Announces Presentations Highlighting Tab-cel and Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced three pr
Read more →ATRAAtara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress
Atara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress SOUTH SAN FRANCISCO, Calif., May 9, 2019 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatment
Read more →ATRAAtara Biotherapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019
SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that its
Read more →ATRAAtara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research (AACR) Annual Meeting 2019
Epstein-Barr virus-specific T cells were engineered to express second-generation CD19 chimeric antigen receptors, eliminated in vitro alloreactivity and inhibited tumor growth in an animal model Off-the-shelf, allogeneic CAR T immunotherapy platform development to advance using
Read more →ATRAAtara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
Memorial Sloan Kettering Cancer Center collaborators presented results that a regionally delivered mesothelin-targeted, autologous CAR T was well-tolerated and showed encouraging anti-tumor activity in combination with pembrolizumab, a PD-1 checkpoint inhibitor Best overall resp
Read more →ATRAAtara Biotherapeutics to Participate in Upcoming Conferences
SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that m
Read more →ATRAAtara Biotherapeutics Announces Presentations Highlighting Next-Generation CAR T Platform and Mesothelin-Targeted CAR T Clinical Results at American Association of Cancer Research (AACR) Annual Meeting 2019
Atara to present off-the-shelf, allogeneic CAR T proof-of-concept results demonstrating Epstein-Barr virus (EBV)-specific T cells expressing chimeric antigen receptors Memorial Sloan Kettering collaborators to present Phase 1 clinical safety and efficacy results of malignant ple
Read more →ATRAAtara Biotherapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Progress
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Progress SOUTH SAN FRANCISCO, Calif., Feb. 26, 2019 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developin
Read more →ATRAAtara Biotherapeutics to Participate in the 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Isa
Read more →ATRAAtara Biotherapeutics Announces Planned Chief Executive Officer Transition
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Is
Read more →ATRAAtara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy for Solid Tumors
Initial results from ongoing Phase 1 study for mesothelin-targeted CAR T support activity and safety in patients with advanced solid tumors Atara’s next-generation CAR T collaboration with MSK to develop mesothelin-targeted CAR T using novel co-stimulatory domain and checkpoint
Read more →ATRAAtara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma (EBV+ LMS)
Second EBV‑associated solid tumor with encouraging responses to tab-cel® Tab-cel® safety appears consistent with a favorable risk profile and previous observations Results were presented today in an oral session at the European Society for Medical Oncology Immuno-Oncology Congr
Read more →ATRAAtara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting
Moffitt Cancer Center collaborators described next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustion Memorial Sloan Kettering collaborators presented positive Phase 2 clinical results for EBV-specific T cell
Read more →ATRAAtara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today presented details
Read more →ATRAAtara Biotherapeutics to Host CAR T Breakfast Teach-In on November 29, 2018
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that th
Read more →ATRAAtara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that re
Read more →ATRAAtara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress
Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress SOUTH SAN FRANCISCO, Calif., November 6, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company dev
Read more →ATRAAtara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hematology (ASH) Annual Meeting and European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2018
Moffitt Cancer Center collaborators to present next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustion Memorial Sloan Kettering collaborators to present new tab-cel® (tabelecleucel) Phase 2 clinical results f
Read more →ATRAAtara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that R
Read more →ATRAAtara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
Focus on multi-targeted CAR T immunotherapies for patients with acute myelogenous leukemia (AML) and B-cell malignancies Collaboration includes novel CAR T targeting and signaling domains designed to optimize T cell proliferation and enhance persistence SOUTH SAN FRANCISCO, Cal
Read more →ATRAAtara Biotherapeutics to Participate at Two Upcoming Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that mem
Read more →ATRAAtara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress
Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress SOUTH SAN FRANCISCO, Calif., August 01, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company deve
Read more →ATRAAtara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Chr
Read more →ATRAAtara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline
SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the open
Read more →ATRAAtara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas
Findings presented at 23rd Congress of European Hematology Association Tab-cel™ demonstrated durable remissions and encouraging safety profile in patients with EBV+ PTLD who failed first line therapy Median survival in SOT patients was 21.3 months and was not reached in the HCT
Read more →ATRAAtara Biotherapeutics Announces Publication of New Research Linking Epstein-Barr Virus (EBV) Infection and Multiple Sclerosis (MS)
SOUTH SAN FRANCISCO, Calif., June 13, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced publicat
Read more →ATRAAtara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., June 07, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Utp
Read more →ATRAAtara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association
SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that the
Read more →ATRAAtara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies in Oncology, Autoimmune and Other Diseases
Entry into genetically engineered T-cells marks next step in Atara’s strategy to advance leadership position in off-the-shelf, allogeneic T-cell immunotherapy SOUTH SAN FRANCISCO, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-t
Read more →ATRAAtara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress
Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress SOUTH SAN FRANCISCO, Calif., May 8, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developi
Read more →ATRAAtara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General Manager, Europe
SOUTH SAN FRANCISCO, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the appoi
Read more →ATRAAtara Biotherapeutics to Participate in Three Upcoming Immuno-Oncology Conferences
SOUTH SAN FRANCISCO, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Chris Haqq, M.
Read more →ATRAAtara Biotherapeutics to Present at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Post-transplant lymphoproliferative disorder (PTLD) following allogeneic hematopoietic cell transplant (HCT) is an aggressive disease impacting a young population and carrying a significant mortality rate in a relatively short time from diagnosis SOUTH SAN FRANCISCO, Calif., Mar
Read more →ATRAAtara Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Isaac Ciechano
Read more →ATRAAtara Biotherapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the pricing of an un
Read more →ATRAAtara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress - Initiated two Phase 3 clinical studies to evaluate tab-cel (tabelecleucel) in patients with Epstein-Ba
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress - Initiated two Phase 3 clinical studies to evaluate tab-cel (tabelecleucel) in patients with Epstein-Barr virus associated post-transplant lymphoproliferative dis
Read more →ATRAAtara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018
Launches Search for Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral d
Read more →ATRAAtara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it received cle
Read more →ATRAwhether as a result of any new information, future events, changed circumstances or otherwise. Risk Factors Investing in our common stock involves a high degree of risk. You should carefully consider all of the risk fact
Unless the context otherwise requires, we use the terms Atara, Atara Biotherapeutics, Atara Bio, Company, we, us and our in this Exhibit 99.1 to refer to Atara Biotherapeutics, Inc. and, where appropriate, our consolidated subsidiaries. Special Note Regarding Forward-Looking St
Read more →ATRAAtara Biotherapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Isaac Ciechanov
Read more →ATRAAtara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)
– Three clinical sites for both the MATCH and ALLELE pivotal studies now open for enrollment in the U.S. – SOUTH SAN FRANCISCO, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing no
Read more →ATRAAtara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein- Barr Virus Associated Post-Transplant Lymphoproliferative Di
Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein- Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Pivotal studies to commence imminently
Read more →ATRAAtara Biotherapeutics to Host Corporate Update Conference Call on Friday, December 29, 2017, at 8:00 a.m. EST
– Company to announce FDA clearance to initiate two Phase 3 tabelecleucel clinical studies – SOUTH SAN FRANCISCO, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments
Read more →ATRAAtara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disorder (PTLD)
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that the Company's c
Read more →ATRAAtara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights
Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., November 9, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatmen
Read more →ATRAAtara Biotherapeutics to Participate in Four Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune diseases and serious viral infections, today announced t
Read more →ATRAAtara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers
Updated ATA230 results in patients with cytomegalovirus (CMV) viremia and disease post-transplant will also be presented SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company
Read more →ATRAAtara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) Infection
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune diseases and serious viral infections, today announced t
Read more →ATRAAtara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190
Three patients in the study improved their Expanded Disability Status Scale (EDSS) score Reduction in fatigue was a consistent observation in responding patients, as highlighted in a presentation at the MSParis 2017 Congress SOUTH SAN FRANCISCO, Calif., Oct. 25, 2017 (GLOBE NEW
Read more →ATRAAtara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS)
Enrollment to begin in Australia; U.S. sites expected to open in early 2018 SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf", or allogeneic, T-cell immunotherapy company developing novel treatment
Read more →ATRAAtara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis (MS)
Five of eight progressive MS patients who received the full course of autologous ATA190 experienced clinical improvements Further results for all 10 patients in the ongoing Phase 1 study will be presented at the MSParis 2017 Congress SOUTH SAN FRANCISCO, Calif., Oct. 16, 2017 (
Read more →ATRAAtara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129
Health Canada New Drug Submission (NDS) planned based on Phase 1 and 2 clinical results and supported by available data from anticipated MATCH and ALLELE Phase 3 studies, which are expected to be ongoing at the time of NDS filing Health Canada regulatory feedback similar to scie
Read more →ATRAAtara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and autoimmune diseases, today announced that ATA230 was granted
Read more →ATRAAtara Biotherapeutics to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS) today announced that the Company will
Read more →ATRAAtara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS), today announced that Atara’s board of
Read more →ATRAAtara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS), today announced the appointment of Ka
Read more →ATRAAtara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights
Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., August 7, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatme
Read more →ATRAAtara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS), today announced that Isaac Ciechanove
Read more →ATRAAtara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis (MS)
New results characterizing the molecular signature of Epstein-Barr Virus (EBV) in MS brain lesions will also be presented Presentations to take place during the upcoming MSParis2017 Congress, the 7th Joint Meeting of the European Committee for Treatment and Research in Multiple
Read more →ATRAAtara Biotherapeutics to Present at Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the Company will present at three upcoming investor conferences in June: Jefferies 2017 Global Healthcare Conference Isaac Ciechanover, M.D., the Company'
Read more →ATRAAtara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team
SOUTH SAN FRANCISCO, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced the appointment of Dr. Derrell Porter as Senior Vice President and Global Commercial Head. Dr. Porter brings extensive commercialization experience to the manag
Read more →ATRAAtara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights
Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., May 4, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today reported financial results for the first quarter of 2017 and recent operationa
Read more →ATRAAtara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC)
SOUTH SAN FRANCISCO, Calif., April 21, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that it has entered into a cli
Read more →ATRAAtara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology
Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017 Encouraging Clinical Improvemen
Read more →ATRAAtara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer
SOUTH SAN FRANCISCO, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today
Read more →ATRAAtara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS)
SOUTH SAN FRANCISCO, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today
Read more →ATRAAtara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights
Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., March 9, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a biopharmaceutical company developing meaningful therapies for patients with
Read more →ATRAAtara Bio to Present at the 35th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today
Read more →ATRAAtara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD)
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today
Read more →ATRAAtara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, to Support Potential Approval in Two Separate Indications
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that it has reached agreement w
Read more →ATRAAtara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today
Read more →ATRAAtara Bio Announces Third Quarter 2016 Financial Results and Recent Highlights
Atara Bio Announces Third Quarter 2016 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., November 4, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and l
Read more →ATRAAtara Bio's Collaborating Investigators to Present Results from Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today
Read more →ATRAAtara Bio Granted Access to Priority Medicines (PRIME) Regulatory Support for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) for Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD)
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today
Read more →ATRAAtara Bio Receives Positive Opinion from EMA on Orphan Drug Designation for Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) for Treatment of CMV Infection in Patients with Impaired Immune Systems
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today
Read more →ATRAAtara Bio to Participate in the Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that Isaac Ciechanover, M.D.,
Read more →ATRAAtara Bio Announces Second Quarter 2016 Financial Results and Recent Highlights
Atara Bio Announces Second Quarter 2016 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., August 8, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with sev
Read more →ATRAAtara Bio to Present at the Canaccord Genuity 36th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that Christopher Haqq, M.D., Ph
Read more →ATRAAtara Bio Doses First Patient in Multi-Center Expanded Access Protocol for Study of Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) in EBV-Associated Lymphomas and Lymphoproliferative Disorders
SOUTH SAN FRANCISCO, Calif., July 12, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced the dosing of its first patient
Read more →ATRAAtara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA)
SOUTH SAN FRANCISCO, Calif., June 23, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that the EMA has classified the
Read more →ATRAAtara Bio to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., June 15, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovat
Read more →ATRAAtara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate
SOUTH SAN FRANCISCO, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life threatening diseases that have been underserved by scientific innovat
Read more →ATRAAtara Bio to Present at Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovati
Read more →ATRAAtara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovati
Read more →ATRAAtara Bio’s Collaborating Investigators to Present Clinical Data on EBV-CTL at 2016 American Transplant Congress
SOUTH SAN FRANCISCO, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovati
Read more →ATRAAtara Bio Announces First Quarter 2016 Financial Results and Recent Highlights
Atara Bio Announces First Quarter 2016 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., May 5, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe
Read more →ATRAAtara Bio’s Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor
Results Highlighted in Oral Presentation at the 2016 American Association for Cancer Research (AACR) Annual Meeting Atara Bio and QIMR Berghofer Collaborating to Develop Next Generation "Off-the-Shelf" T Cell Immunotherapy for NPC and Other Diseases SOUTH SAN FRANCISCO, Calif.,
Read more →ATRAAtara Bio to Present at the 15th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 06, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today
Read more →ATRAAtara Bio Announces Participation in Two Upcoming Immuno-Oncology Conferences
SOUTH SAN FRANCISCO, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today
Read more →ATRAAtara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder
SOUTH SAN FRANCISCO, Calif., March 23, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today
Read more →ATRAAtara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innova
Read more →ATRAAtara Bio Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Highlights South San Francisco, CA
Atara Bio Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Highlights South San Francisco, CA- March 3, 2016 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and
Read more →ATRAAtara Bio to Present at the Cowen and Company 36th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovat
Read more →ATRAAtara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD)
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovat
Read more →ATRAAtara Bio Announces Participation in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today
Read more →ATRAAtara Bio to Present at the 34th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today
Read more →ATRAAtara Bio Added to the NASDAQ Biotechnology Index
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today
Read more →ATRAAtara Bio Announces Results from the Phase 2 Proof-of-Concept PINTA 745 Clinical Trial for Protein Energy Wasting in Patients with End Stage Renal Disease Atara Bio to Host Conference Call and Webcast Today at 8:00 a.m.
Atara Bio Announces Results from the Phase 2 Proof-of-Concept PINTA 745 Clinical Trial for Protein Energy Wasting in Patients with End Stage Renal Disease Atara Bio to Host Conference Call and Webcast Today at 8:00 a.m. Eastern Time South San Francisco, CA- December 14, 2015 -
Read more →ATRAAtara Bio Announces Positive Results From a Phase 2 Clinical Trial of Cytomegalovirus Targeted Cytotoxic T Lymphocytes (CMV-CTL), a Novel Approach to Adoptive Immunotherapy, to Treat Patients With Refractory CMV Disease in the Central Nervous System (CNS)
Overall Response Rate >70% and no GvHD Observed in Patients with Refractory CMV Chorioretinitis or Meningoencephalitis Findings Reported at American Society of Hematology (ASH) Annual Meeting 2015 SOUTH SAN FRANCISCO, Calif., Dec. 06, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeut
Read more →ATRAAtara Bio Announces Positive Results From Phase 1 Clinical Trial of Wilms’ Tumor 1 Targeted Cytotoxic T Lymphocytes (WT1-CTL) Product Candidate in Hematologic Malignancies
Response Duration >2 Years Observed in a Patient with Plasma Cell Leukemia Findings Reported at American Society of Hematology (ASH) Annual Meeting 2015 SOUTH SAN FRANCISCO, Calif., Dec. 05, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical
Read more →ATRAAtara Bio’s Collaborating Investigators to Present Data From Two Cellular Therapy Product Candidates at the American Society of Hematology (ASH) Annual Meeting 2015
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today
Read more →ATRAAtara Biotherapeutics Announces Third Quarter 2015 Financial Results South San Francisco, Calif.
Atara Biotherapeutics Announces Third Quarter 2015 South San Francisco, Calif., November 5, 2015 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen
Read more →ATRAAtara Biotherapeutics Announces Participation in Three Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, t
Read more →ATRAAtara Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Exclusive License and Research Agreements
SOUTH SAN FRANCISCO, Calif. and BRISBANE, Australia, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited t
Read more →ATRAAtara Bio Receives FDA Orphan Drug Designation for STM 434, Atara Bio's Activin Inhibitor for Ovarian Cancer
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, t
Read more →ATRAAtara Bio to Host Investor Day on October 21, 2015
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc., (Nasdaq:ATRA), today announced that the Company will host a live webcast in conjunction with its Investor Day on Wednesday, October 21, 2015 at 12:00p.m. ET in New York, NY. The live audi
Read more →ATRAAtara Bio’s PINTA 745 Improves Insulin Sensitivity and Alters Fat Metabolism in Mice Fed With a High Fat Diet
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the publication of preclinical data that
Read more →ATRAAtara Bio’s Collaborating Investigators to Present Data at the American Society of Nephrology Kidney Week 2015
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that its collaborating investigators at B
Read more →ATRAAtara Bio's T-Cell Product Candidate Activated Against Wilms' Tumor 1 Protein Demonstrates Encouraging Results in Patients With Plasma Cell Leukemia
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) presented clinical data on cytotoxic T lymphocytes (CTL) activated again
Read more →ATRAAtara Biotherapeutics, Inc. to Present at Upcoming Investor Conferences in September 2015
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that it will present at the investor conferences listed below. Citi's 10th Annual Biotech Conference at 11:00 a.m. EDT, Thursday, September 10, 2015 at the Ma
Read more →ATRAAtara Biotherapeutics Announces Completion of Enrollment in PINTA 745 Phase 2 Clinical Trial in End-Stage Renal Disease Patients With Protein Energy Wasting
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that it completed enrollment in its blind
Read more →ATRAAtara Biotherapeutics Announces Second Quarter 2015 Results South San Francisco, Calif.
Atara Biotherapeutics Announces Second Quarter 2015 Results South San Francisco, Calif., August 6, 2015 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today report
Read more →ATRAAtara Bio Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the closing of its underwritten public of
Read more →ATRAAtara Bio Announces Pricing of Its $180.0 Million Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the pricing of its underwritten public off
Read more →ATRAAtara Bio Announces Proposed Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that it has commenced an underwritten publ
Read more →ATRAAtara Biotherapeutics Exercises Exclusive License to T-Cell Technology From Memorial Sloan Kettering Cancer Center
SOUTH SAN FRANCISCO, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that it has exercised its exclusive option with Memorial Sloan Kettering Cancer Center (MSK) to license certain clinical stage, allogeneic T-cell therapies for
Read more →ATRAAtara Biotherapeutics, Inc. to Present at Upcoming Investor Conferences in June 2015
SOUTH SAN FRANCISCO, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that it will webcast its presentations at the below listed investor conferences in June 2015. Isaac Ciechanover, the company's President and Chief Executive Of
Read more →ATRAAtara Biotherapeutics' Collaborating Investigators to Present Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present clinical data from two studies of cytotoxic T lymphocytes acti
Read more →ATRAAtara Biotherapeutics, Inc. to Present at the UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Isaac Ciechanover, the company's President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on Monday, May 18, 2015 at 4:0
Read more →ATRAAtara Biotherapeutics Announces First Quarter 2015 Results
SOUTH SAN FRANCISCO, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today reported financial results for the first quarter end
Read more →ATRAAtara Biotherapeutics' Collaborating Investigators' Abstract on T-Cell Therapy for EBV Lymphoma to be Presented at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015 is Now Available
SOUTH SAN FRANCISCO, Calif., April 19, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that the abstract on cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) that will be presented by its collaborating investigators at Memo
Read more →ATRAAtara Biotherapeutics, Inc. to Present at the 2015 Jefferies Immuno-Oncology Summit
SOUTH SAN FRANCISCO, Calif., April 13, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Isaac Ciechanover, M.D., the company's Chief Executive Officer, will present at the 2015 Jefferies Immuno-Oncology Summit on Wednesday, April 15, 2015 at
Read more →ATRAAtara Biotherapeutics, Inc. to Present at the Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Gad Soffer, the company's Chief Operating Officer, will present at the 2015 Needham Healthcare Conference on Tuesday, April 14, 2015 at 5:00 pm EDT in New
Read more →ATRAAtara Biotherapeutics, Inc. Appoints Eric Dobmeier, Chief Operating Officer of Seattle Genetics, Inc., to Its Board of Directors
SOUTH SAN FRANCISCO, Calif., March 27, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases, today announced that Eric Dobmeier has joined its Board of Di
Read more →ATRAAtara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV Lymphoma at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015
SOUTH SAN FRANCISCO, Calif., March 19, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present clinical data from two studies of cytotoxic T lymphocytes a
Read more →ATRAAtara Biotherapeutics Names David A. Carmel as Head of Immunotherapy
SOUTH SAN FRANCISCO, Calif., THOUSAND OAKS, Calif., and NEW YORK, March 3, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on innovative therapies for patients with debilitating diseases, announced today that it has hired Da
Read more →ATRAAtara Biotherapeutics Announces Fourth Quarter and Full Year 2014 Operating Results
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today reported financial results for the fourth quarter a
Read more →ATRAAtara Biotherapeutics Announces Closing of Underwritten Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced the closing of its public offering of 4,
Read more →ATRAAtara Bio Announces Pricing of Its $65.5 Million Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its underwritten public o
Read more →ATRAAtara to Present at the J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that Isaac Ciechanover, M.D., the company
Read more →ATRAAtara Biotherapeutics Announces Third Quarter 2014 Operating Results
BRISBANE, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today reported financial results for the third quarter and nine mon
Read more →ATRAAtara Biotherapeutics' Collaborating Investigators to Present Data at the American Society of Hematology Annual Meeting 2014
BRISBANE, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that its collaborating investigators at Memorial Slo
Read more →ATRAAtara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor
BRISBANE, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced dosing of the first patient in its Phase 1 clinical study of STM
Read more →ATRAAtara Biotherapeutics (Nasdaq: ATRA) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
ADVISORY, Oct. 15, 2014 (GLOBE NEWSWIRE) -- -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs, will visit the NASDAQ MarketSite in Times Square in celebration of its i
Read more →ATRAAtara Biotherapeutics Announces Pricing of Its Initial Public Offering
BRISBANE, Calif., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its initial public offering of 5,000,000 shares o
Read more →ATRAAtara Biotherapeutics Announces Immunotherapy Alliance With Memorial Sloan Kettering Cancer Center
BRISBANE, Calif., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics (Atara) today announced that they have entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies
Read more →Competitive Position
How ATRA ranks across every disease it competes inCompetitive Position is a premium feature
See how ATRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial